Drug Profile
Sapacitabine - Daiichi Sankyo Company
Alternative Names: CS-682; CYC-682Latest Information Update: 08 Jun 2023
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company; Hokkaido University; Kanazawa University
- Developer Cyclacel Pharmaceuticals; Leukaemia & Lymphoma Research; University of Texas M. D. Anderson Cancer Center
- Class Amides; Antineoplastics; Arabinonucleosides; Pyrimidines; Small molecules
- Mechanism of Action Antimetabolites; Cell cycle inhibitors; DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Breast cancer; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Myelodysplastic syndromes; Non-small cell lung cancer; Ovarian cancer; Precursor B-cell lymphoblastic leukaemia-lymphoma; Solid tumours
Most Recent Events
- 14 Apr 2023 Safety, efficacy and pharmacodynamics data froma phase Ib/II trial in Breast cancer presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 23 Mar 2023 Cyclacel Pharmaceuticals terminates its licence for sapacitabine with Daiichi Sankyo
- 09 Nov 2022 Cyclacel Pharmaceuticals plans to terminate license agreement with Daiichi Sankyo in March 2023